Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBIT (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBIT for 11 consecutive years, with -$78.6 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 194.19% to -$78.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$143.4 million through Dec 2025, down 226.69% year-over-year, with the annual reading at -$143.4 million for FY2025, 226.69% down from the prior year.
  • EBIT for Q4 2025 was -$78.6 million at Cartesian Therapeutics, down from -$21.1 million in the prior quarter.
  • The five-year high for EBIT was $13.9 million in Q2 2022, with the low at -$78.6 million in Q4 2025.
  • Average EBIT over 5 years is -$13.2 million, with a median of -$13.2 million recorded in 2023.
  • The sharpest move saw EBIT soared 2966.37% in 2022, then tumbled 717.07% in 2023.
  • Over 5 years, EBIT stood at $4.1 million in 2021, then crashed by 308.34% to -$8.5 million in 2022, then tumbled by 327.64% to -$36.3 million in 2023, then grew by 26.43% to -$26.7 million in 2024, then crashed by 194.19% to -$78.6 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$78.6 million, -$21.1 million, and -$21.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.